Agency efforts to standardise benefit:risk assessment progress
This article was originally published in Scrip
The European Medicines Agency has released results from the first of a five-part project that aims to standardise for the first time the way in which it assesses the benefits and risks of medicines.
You may also be interested in...
Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
New medicines under evaluation at the European Medicines Agency.